<DOC>
	<DOCNO>NCT01724138</DOCNO>
	<brief_summary>To characterize PK deferasirox pediatric β-thalassemia major patient age 2 less 6 year old , administrate fix start dose 20 mg/kg/day .</brief_summary>
	<brief_title>An Open Label Study Evaluate Pharmacokinetics , Safety , Tolerability Efficacy Deferasirox Administered Chinese Patients With β-thalassemia Major Aged From 2 Less Than 6 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Pediatric patient age 2 less 6 year old . Patients transfusion dependent βthalassemia major . Serum ferritin value ≥ 1000 ng/ml screen . Written informed consent must obtain patient 's legal guardian accordance local law regulation prior screen procedure . Nontransfusiondependent thalassemia . Systemic disease would prevent study treatment ( e.g . uncontrolled hypertension , cardiovascular , renal , hepatic , metabolic , etc . ) Serum creatinine &gt; age adjust ULN . Significant proteinuria indicate urinary protein/creatinine ratio ( UPCR ) ≥ 0.5mg/mg nonfirst void urine sample screening . If UPCR find ≥ 0.5 mg/mg test repeat 1 month . ALT/AST &gt; 2.5xULN total bilirubin &gt; 1×ULN . Left ventricular ejection fraction &lt; 56 % echocardiography . Patient known history HIV seropositivity history active/treated hepatitis B C ( test screening require ) . A history clinically relevant ocular and/or auditory toxicity relate iron chelation therapy Any surgical medical condition significantly alter absorption , distribution , metabolism excretion drug ( e.g . ulcerative disease , uncontrolled nausea , vomit , malabsorption syndrome , obstruction , stomach and/or small bowel resection ) . Other condition investigator deem potential harm patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>deferasirox</keyword>
</DOC>